Co-administration of Shingles and RSV Vaccines Produces Positive Data

GSK plc recently announced topline Phase 3 clinical trial data for a combination regimen of two of its vaccines: the RSV vaccine Arexvy and Shingrix, a market-leading shingles shot.

While GSK did not provide specific clinical trial (NCT05966090) data in its September 18, 2024 announcement, the company did confirm that co-administering Arexvy with Shingrix resulted in a “non-inferior immune response” compared with inoculation with the vaccines at separate visits.

The vaccine combo was also well-tolerated with an “acceptable” safety profile, according to GSK.

This is essential news as both RSV and shingles pose significant health risks to older adults, and these risks only increase with age as the immune system declines.

“With our co-administration studies, GSK is using its science and technology to help remove barriers to adult immunization, by potentially reducing the number of visits to the healthcare offices and pharmacies and ultimately help to get ahead of RSV and shingles,” Led Friedland, GSK’s vice president of scientific affairs and public health, said in the statement.

Results from this trial will be submitted for peer-reviewed scientific publication and used to support regulatory submissions to the U.S. FDA, the European Medicines Agency, and other regulators.